Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELT-300 for Procedural Sedation in Cataract Surgery
NCT06383273Phase 3Recruiting
- Sponsor
- Melt Pharmaceuticals
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of midazolam + ketamine in cataract, sponsored by Melt Pharmaceuticals. Started May 2024; status: recruiting.
02
Drugs
midazolam + ketamine
03
Conditions
cataract
Beyond the preview
Go deeper on NCT06383273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383273.